| CHMP | Committee for Medicinal Products for Human Use (Ausschuss für Humanarzneimittel) |
| CKD | Chronic Kidney Desease |
| CRI | Chronic Renal Insufficiency (Chronische Niereninsuffizienz) |
| EMA | European Medicines Agency (Europäische Arzneimittelagentur) |
| EPAR | European Public Assessment Report (Europäischer Öffentlicher Beurteilungsbericht) |
| EPO | Erythropoetin, Erythropoietin, Epoetin |
| FDA | Food and Drug Administration |
| G-CSF | Granulocyte colony-stimulating factor |
| GHDA | Growth Hormone Deficiency in Adults |
| GMP | Good Manufacturing Practice |
| hGH | human Growth Hormone |
| IGF-1 | Insulin-like Growth Factor 1 |
| IGFBP-3 | Insulin-like Growth Factor Binding Protein 3 |
| INN | International non-proprietary name (Internationaler Freiname) |
| PGHD | Pediatric Growth Hormone Deficiency |
| PMS | Post-Marketing Surveillance |
| PWS | Prader-Willi-Syndrom |
| SGA | Small for gestational age |
| UTS | Ullrich-Turner-Syndrom |
